These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28508264)

  • 1. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
    Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
    BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
    Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
    Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
    Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
    Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
    Troccoli NM; McIver J; Losikoff A; Poiley J
    Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process.
    Trejo SR; Hotta JA; Lebing W; Stenland C; Storms RE; Lee DC; Li H; Petteway S; Remington KM
    Vox Sang; 2003 Apr; 84(3):176-87. PubMed ID: 12670366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
    Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
    Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
    Burnouf T; Terpstra F; Habib G; Seddik S
    Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
    Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
    Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
    Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
    Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
    Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
    Gugerell A; Sorgenfrey D; Laggner M; Raimann J; Peterbauer A; Bormann D; Suessner S; Gabriel C; Moser B; Ostler T; Mildner M; Ankersmit HJ
    Blood Transfus; 2020 Jan; 18(1):30-39. PubMed ID: 30865581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robustness of nanofiltration for increasing the viral safety margin of biological products.
    Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
    Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.